Metformin Down-regulates Endometrial Carcinoma Cell Secretion of IGF-1 and Expression of IGF-1R |
Zhang, Yu
(Department of Gynecology The Third Affiliated Hospital of Sun Yat-Sen University)
Li, Meng-Xiong (Department of Gynecology The Third Affiliated Hospital of Sun Yat-Sen University) Wang, Huan (Department of Gynecology The Third Affiliated Hospital of Sun Yat-Sen University) Zeng, Zheng (Department of Gynecology The Third Affiliated Hospital of Sun Yat-Sen University) Li, Xiao-Mao (Department of Gynecology The Third Affiliated Hospital of Sun Yat-Sen University) |
1 | Lacey JV Jr, Potischman N, Madigan MP, et al (2004). Common genetic variation within IGFI, IGFII, IGFBP-1, and IGFBP-3 and endometrial cancer risk. Cancer Epidemiol Biomarkers Prev, 4, 607-12. |
2 | Luo Z, Zang M, Guo W (2010). AMPK as a metabolic tumor suppressor: control of metabolism and cell growth. Future Oncol, 6, 457-70. DOI |
3 | Liu B, Fan Z, Edgerton SM, et al (2011). Potent anti- proliferative effects of metformin on trastuzumab- resistant breast cancer cells via inhibition of erbB2/IGF-1 receptor interactions. Cell Cycle, 10, 2959-66. DOI |
4 | Leone A, Di Gennaro E, Bruzzese F, et al (2014). New perspective for an old antidiabetic drug: metformin as anticancer agent. Cancer Treat Res, 159, 355-76. DOI |
5 | Liang K, Qiu S, Lu Y (2014). Autocrine/paracrine erythropoietin regulates migration and invasion potential and the stemness of human breast cancer cells. Cancer Biol Ther, 1, 89-98. |
6 | Morrow CP, Curtin JP, Townsend DE (1993). Tumors of the endometrium, in Synopsis of Gynecologic Oncology, 4th ed., New York, NY: Churchill Livingstone, 209. |
7 | Morrison KB, Tognon CE, Garnett MJ, et al (2002). ETV6-NTRK3 transformation requires insulin-like growth factor 1 receptor signaling and is associated with constitutive IRS-1 tyrosine phosphorylation. Oncogene, 21, 5684-95. DOI |
8 | Martin-Castillo B, Vazquez-Martin A, Oliveras-Ferraros C, et al (2010). Metformin and cancer: Doses, mechanisms and the dandelion and hormetic phenomena. Cell cycle, 9, 1057-64. DOI |
9 | Markowska A, Pawalowska M, Filas V, et al (2014). Does Metformin affect ER, PR, IGF-1R, beta-catenin and PAX-2 expression in women with diabetes mellitus and endometrial cancer? Diabetol Metab Syndr, 1, 76. |
10 | Nathan DM, Buse JB, Davidson MB, et al (2009). Medical management of hyperglycemia in type 2 diabetes mellitus: A consensus algorithm for the initiation and adjustment of therapy-A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia, 52, 17-30. DOI |
11 | Nevadunsky NS, Van Arsdale A, Strickler HD, et al (2014). Metformin use and endometrial cancer survival. Gynecol Oncol, 1, 236-40. |
12 | Pearl MP, Talavera F, Gretz HG, et al (1993). Mitogenic activity of growth factors in the human endometrial cancer cell lines HEC 1A and KLE. Gynecol Oncol, 49, 325-32. DOI |
13 | Pavelic Jasminka, Radakovic Branko, Pavelic Kresimir (2007). Insulin-like growth factor -2 and its receptors (IGF-1R and IGF-2R / mannose-6-phosphate) in endometrial adenocarcinoma. Gynecol Oncol, 105, 727-35. DOI |
14 | Pollak M (2010). Metformin and other biguanides in oncology: advancing the research agenda. Cancer Prev Res, 3, 1060-5. DOI |
15 | Rozengurt E, Sinnett-Smith J, Kisfalvi K (2010). Crosstalk between insulin/insulin-like growth factor-1 receptors and G protein-coupled receptor signaling systems: a novel target for the antidiabetic drug metformin in pancreatic cancer. Clin Cancer Res, 16, 2505-11. DOI ScienceOn |
16 | Sachdev D, Hartell JS, Lee AV, et al (2004). A dominant negative type I insulin-like growth factor receptor inhibits metastasis of human cancer cells. J Biol Chem, 279, 5017-24. |
17 | Samani AA, Chevet E, Fallavollita L, et al (2004). Loss of tumorigenicity and metastatic potential in carcinoma cells expressing the extracellular domain of thetype 1 insulin-like growth factor receptor. Cancer Res, 64, 3380-5. DOI |
18 | Salani B, Del Rio A, Marini C, et al (2014). Metformin, cancer and glucose metabolism. Endocr Relat Cancer, 6, 461-71. |
19 | Shaw RJ, Lamia KA, Vasquez D, et al (2005). The kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metformin. Science, 310, 1642-6. DOI |
20 | Shu SR, Li XM, Yang YB, et al (2011). Inhibitory effect of siRNA targeting IGF-1R on endometrial carcinoma. International Immunopharmacology, 2, 244-9. |
21 | Sarkissyan S, Sarkissyan M, Wu Y, et al (2014). IGF-1 regulates Cyr61 induced breast cancer cell proliferation and invasion. PLoS One, 7, 103534. |
22 | Torng PL, LeeYC, Huang CY, et al (2008). Insulin- like growth factor protein- 3 (IGFBP- 3) act as an invasion- metastas is suppressor in ovarian endometrial carcinoma. Oncogene, 27, 2137-47. DOI |
23 | Weiderpass E, Brismar K, Bellocco R, et al (200\3). Serum levels of insulin-like growth factor-I, IGF-binding protein 1 and 3, and insulin and endometrial cancer risk. Br J Cancer, 9, 1697-704. |
24 | Xie Y, Wang YL, Yu L, et al (2011). Metformin promotes progesterone receptor expression via inhibition of mammalian target of rapamycin (mTOR) in endometrial cancer cells. J Steroid Biochem Molec Biol, 126, 113-20. DOI |
25 | Xu JN, Zeng C, Zhou Y, et al (2014). Metformin inhibits StAR expression in human endometriotic stromal cells via AMPKmediated disruption of CREB-CRTC2 complex formation. J Clin Endocrinol Metab, 8, 2795-803. |
26 | Zhou J, Dsupin BA, Giudice LC, Bondy CA (1994). Insulinlike growth factor system gene expression in human endometrium during the menstrual cycle. J Clin Endocrinol Metab, 79, 1723-34. |
27 | Barakat RR, Grisby PW, Sabbatini. Corpus: epithelial tumor (2007). In: Hoskin WJ, Perez CA, Young RC principles and practice of gynecologic oncology, 2rd. Lippincott Williams & Wilkins, Philadelphia, 919-59. |
28 | Zhou G, Myers R, Li Y, et al (2001). Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest, 108, 1167-74. DOI |
29 | Arian ER, Pascale F, Anne TN, et al (2013). Metformin and cancer: from the old medicine cabinet to pharmacological pitfalls and prospects.Trends in Pharmacological Sciences, 2, 126-35. |
30 | Baserga R (1995). The insulin-like growth factor I receptor: a key to tumor growth? Cancer Res, 55, 249-52. |
31 | Bershtein LM (2014). Endometrial cancer, estrogens and metabolic syndrome: scenario becomes more complicated. Vopr Onkol, 3, 254-62. |
32 | Casamassima A, Rozengurt E (1998). Insulin-like growth factor I stimulates tyrosine phosphorylation of p130 (Cas), focal adhesion kinase, and paxillin. Role of phosphatidylinositol 3'-kinase and formation of a p130 (Cas). Crk complex. J Biol Chem, 273, 26149-56. DOI |
33 | Creighton CJ, Casa A, Lazard Z, et al (2008). Insulin-like growth factor-I activates gene transcription programs strongly associated with poor breast cancer prognosis, J Clin Oncol, 25, 4078-85. |
34 | Derynck R, Goeddel DV, Ullrich A, et al (1987). Synthesis of messenger RNAs for transforminggrowth factors a and b and the epidermal growth factor receptor by human tumors. Cancer Res, 47, 707-12. |
35 | Goodwin PJ, Pritchard KI, Ennis M, et al (2008). Insulinlowering effects of metformin in women with early breast cancer. Clin Breast Cancer, 8, 501-5. DOI |
36 | Eugenio M, Giuseppe L, Giuseppe V, et al (1999). Insulinlike growth factor-1 expression in normal and diseased endometrium. Int J Cancer, 80, 188-93. DOI |
37 | Gunter MJ, Hoover DR, Yu H, et al (2008). A prospective evaluation of insulin and insulin-like growth factor-I as risk factors for endometrial cancer. Cancer Epidemiol Biomarkers Prev, 4, 921-9. |
38 | Goustin AS, Leof EB, Shipley GD, et al (1986). Growth factors and cancer. Cancer Res, 46, 1015-29. |
39 | Haining RE, Schofield JP, Jones DS, et al (1991). Identification of mRNA for epidermal growth factor and transforming growth factor-alpha present in low copy number in human endometrium and decidua using reverse transcriptasepolymerase chain reaction. J Mol Endocrinol, 6, 207-14. DOI |
40 | Hirano S, Ito N, Takahashi S, et al (2004). Clinical implications of insulin-like growth factors through the presence of their binding proteins and receptors expressed in gynecological cancers. Eur J Gynaecol Oncol, 25, 187-91. |
41 | Kisfalvi K, Eibl G, Sinnett-Smith J, et al (2009). Metformin disrupts crosstalk between G protein-coupled receptor and insulin receptor signaling systems and inhibits pancreatic cancer growth. Cancer Res, 69, 6539-45. DOI |
42 | Lelle' RJ, Talavera F, Gretz HG, et al (1993). Epidermal growth factor receptor expression in three different human endometrial cancer cell lines. Cancer, 72, 519 -25. DOI |
43 | Lukanov A, Zeleniuch- Jacquotte A, Lundin E, et al (2004). Prediag no st ic level o f C- peptide, IGF- 1, IGFBP- 1, - 2 and- 3 and r isk o f endometr ial cancer. Int J Cancer, 2, 262-8. |